Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

INTRODUCTION: Since current treatment options for patients suffering from active rheumatoid arthritis (RA) remain inadequate, especially for those unresponsive to disease-modifying antirheumatic drugs (DMARDs), new and improved medication is needed. This study evaluates the safety and efficacy of ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Tebib, Jacques, Mariette, Xavier, Bourgeois, Pierre, Flipo, René-Marc, Gaudin, Philippe, Le Loët, Xavier, Gineste, Paul, Guy, Laurent, Mansfield, Colin D, Moussy, Alain, Dubreuil, Patrice, Hermine, Olivier, Sibilia, Jean
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714151/
https://www.ncbi.nlm.nih.gov/pubmed/19549290
http://dx.doi.org/10.1186/ar2740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714151/
https://www.ncbi.nlm.nih.gov/pubmed/19549290
http://dx.doi.org/10.1186/ar2740

Ejemplares similares